Stock Market Reviews

Read and share opinions on IMNN (Imunon, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Imunon Inc (IMNN) Q3 2025 Earnings Call Highlights: Promising Advances in Immunotherapy and ...
  Nov 13, 2025
• Imunon (IMNN) Q3 2025 Earnings Call Transcript
  Nov 13, 2025
• IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
  Nov 13, 2025
• IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
  Nov 10, 2025
• IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
  Nov 10, 2025
• IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
  Nov 7, 2025
• IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025
  Nov 6, 2025
• IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
  Nov 4, 2025
• IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
  Oct 30, 2025
• IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
  Oct 23, 2025
• IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
  Oct 17, 2025
• IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
  Oct 14, 2025
• IMNN: OVATION 2 Translational Data Shows IMNN-001 Alters Tumor Microenvironment…
  Sep 23, 2025
• IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
  Sep 22, 2025
• IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
  Sep 19, 2025
• IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
  Sep 2, 2025
• IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
  Aug 28, 2025
• IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial…
  Aug 7, 2025
• Imunon Inc (IMNN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
  Aug 6, 2025